Breaks Categories: News

WednesdayApr 14, 2021 12:19 pm

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Prepares to Commence Retail Sales of Gummie Products

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, today announced that it has commenced production on approximately 50,000 Pure Chews edible gummie packs. Demand for these types of products is strong in the four provinces (British Columbia, Alberta, Saskatchewan and Ontario) that Pure Extracts is targeting for its retail launch, with approximately $200,000 in revenue estimates associated with this batch. All Pure Chews SKUs, including the 10 mg THC packs of Fire Burst, Strawberry and Mango, utilize a proprietary manufacturing system licensed from…

Continue Reading

TuesdayApr 13, 2021 10:37 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Advancement of IND-Enabling Studies of Psychedelic Molecules for IND Applications

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has plans to advance the preclinical work for two of its deuterated tryptamine development candidates: its orally dissolving tablet (“ODT”) formulation of CYB003 and its inhaled formulation of CYB004. In the announcement, the company noted that the planned studies are part of the required U.S. Food and Drug Administration (“FDA”) enabling trials for investigational new drug applications (“INDs”). The results of the studies will be included in the submissions to the FDA and other regulatory bodies, including Health Canada and European Medical Association (“EMA”). The proprietary Cybin…

Continue Reading

FridayApr 09, 2021 9:23 am

PsychedelicNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Announces Strategic Equity Investment in Psychedelic Journey Center

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology for psychedelic therapy, has announced a follow-up strategic equity investment in ATMC Journey Centers Inc. ("ATMA"), the first government-approved psychedelic journey center in Canada. Earlier this year, MCUR had signed a letter of intent, securing 13% ownership in ATMA; this additional investment retains that ownership. In addition, the company named Mind Cure Health president and CEO Kelsey Ramsden to the ATMA board of directors. MINDCURE’s investment into the pioneering psychedelic journey center is meant to facilitate the use of iSTRYM (“iSTRYM”), which is MCUR’s proprietary…

Continue Reading

ThursdayApr 08, 2021 9:57 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Announces Plans to Launch 1st US Initiative into Dynamic Michigan Market

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, today announced its entry into a letter of intent (“LOI”) with the affiliate of a publicly traded multistate operator (“MSO”) to form a joint venture (the “JV”) to install a cannabis and hemp extraction system in an existing Michigan facility. According to the update, the MSO has a long history of success in Oregon, offering a family of products that include sun-grown and indoor premium flower, along with patented nitro-sealed indoor and sun-grown pre-rolls and…

Continue Reading

WednesdayMar 31, 2021 10:52 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Enters LOI for Psilocybin Extraction, Development of Formulations

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, has inked a letter of intent (“LOI”) to form a joint venture (“JV”) with Psyence Group Inc. (CSE: PSYG). The agreement with Psyence, one of the world’s first psychedelic mushroom companies operating a federally legal commercial cultivation and extraction facility in Southern Africa, calls for the development of high-class techniques for the extraction of psilocybin from psychedelic mushrooms as well as the development of advanced formulations containing psilocybin for the long-term treatment of psychological trauma and…

Continue Reading

TuesdayMar 30, 2021 9:59 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Appoints New Management Positions, Focused on Development and Clinical Operations

Cybin (NEO: CYBN) (OTCQB: CLXPF) announced changes in senior management positions. Cybin US Holdings Inc.’s new chief clinical officer will be Alexander Belser, PhD and its new chief operating officer will be Aaron Bartlone. In addition, co-founder and former COO Paul Glavine has been named chief growth officer and co-founder of Cybin Inc., while former SVP of business development John Kanakis will become chief business officer. The changes are effective immediately. An accomplished biopharmaceutical executive with a proven track record across numerous therapeutic and functional areas, Bartlone has extensive experience with quality assurance, regulatory affairs, product development, compliance and commercial…

Continue Reading

MondayMar 22, 2021 10:41 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Enters Strategic Drug Development Agreement with Catalent Inc. (NYSE: CTLT)

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced its entry into a drug development agreement with Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. According to the update, Cybin will be applying Catalent’s proprietary Zydis(R) orally disintegrating tablet (“ODT”) technology for the delivery of its novel deuterated tryptamine (“CYB003”), a potential therapy for treatment-resistant psychiatric disorders. “We are excited to partner with the team at Catalent with the aim of developing fast-acting, shorter-duration formulations of…

Continue Reading

WednesdayMar 17, 2021 11:37 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Advances Psychedelic IND Candidates, Announces Completion of 20th Preclinical Study

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced completion of its 20th preclinical study and is progressing its CYB003 and CYB004 proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies. According to the update, Cybin, through collaboration with its partners and contractors, has completed key research studies both in-vitro and in-vivo. Based on proprietary Cybin technologies, more than 20 definitive research studies designed by the company’s scientists were completed in record time. “Excellent teamwork and fully supportive partners have greatly facilitated the advancement of these two new therapeutic candidates with enhanced and improved…

Continue Reading

WednesdayMar 17, 2021 9:49 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Announces Subsidiary Has Ordered First Shipment of Functional Mushrooms

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) subsidiary Pure Mushrooms Corp. has placed its first order for functional mushrooms from a British Columbia co-packer. Pure Mushrooms will use the mushrooms to produce three products, which will be offered through the company’s online e-commerce store. Previously Pure Mushrooms had developed three premium formulations based on reishi, maitake and lion’s mane mushrooms. These formulations, which are delivered in convenient vegan capsules, will be the foundation of the upcoming new products. Rreishi and maitake formulations should go on sale in April, with the  lion’s mane release slated for June. The announcement…

Continue Reading

TuesdayMar 16, 2021 12:02 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at Oppenheimer Health Care Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that its Chief Executive Officer, Doug Drysdale, will be presenting a business and pipeline update at the Oppenheimer 31st Annual Healthcare Conference. Drysdale’s presentation is scheduled to begin at 11:20 a.m. Eastern Time on Thursday, March 18, 2021. Interested parties should visit https://ibn.fm/ZE9G5 to register for the event. The presentation will be webcast live at the aforementioned time and available for seven days thereafter via the above link. To view the full press release, visit https://ibn.fm/ZWvHk About Cybin Inc. Cybin is a leading biotechnology company…

Continue Reading